國立高雄大學圖資館 |

Language: English

Back

Immunotherapy

Hajjar, Joud.

Immunotherapy

Record Type:	Electronic resources : Monograph/item
Title/Author:	Immunotherapyedited by Aung Naing, Joud Hajjar.
other author:	Naing, Aung.
Published:	Cham :Springer International Publishing :2020.
Description:	xii, 339 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Immunotherapy.
Online resource:	https://doi.org/10.1007/978-3-030-41008-7
ISBN:	9783030410087$q(electronic bk.)

Immunotherapy
Immunotherapy[electronic resource] /edited by Aung Naing, Joud Hajjar. - Third edition. - Cham :Springer International Publishing :2020. - xii, 339 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.12440065-2598 ;. - Advances in experimental medicine and biology ;946..

Overview of Basic Immunology and Clinical Application -- Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: From a minor God to the Olympus -- Immunotherapy in Gastrointestinal Malignancies -- Current Landscape of Immunotherapy in Genitourinary Malignancies -- Immuno-oncology for Gynecologic Malignancies -- Immunotherapy for Neuro-Oncology -- Immunotherapy and Radiation -- CAR T-cells -- Skin Reactions to Immune Checkpoint Inhibitors -- Gastrointestinal Tract Adverse Events -- Immune-Related Adverse Events: Pneumonitis -- Hepatobiliary Adverse Events -- Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity -- Renal Toxicity -- Immune-Related Oral, Otologic and Ocular Adverse Events -- Cancer Imaging in Immunotherapy -- The Microbiome in Immuno-Oncology -- New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies.

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.

ISBN: 9783030410087$q(electronic bk.)

Standard No.: 10.1007/978-3-030-41008-7doiSubjects--Topical Terms:

211033
Immunotherapy.

LC Class. No.: RM275 / .I468 2020

Dewey Class. No.: 615.37

Immunotherapy
LDR:04047nmm a2200349 a 4500 001 571677
003 DE-He213
005 20200810164712.0
006 m d
007 cr nn 008maaau
008 200922s2020 sz s 0 eng d
020 $a 9783030410087$q(electronic bk.)
020 $a 9783030410070$q(paper)
024 7 $a 10.1007/978-3-030-41008-7 $2 doi
035 $a 978-3-030-41008-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RM275 $b .I468 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 615.37 $2 23
090 $a RM275 $b .I33 2020
245 0 0 $a Immunotherapy $h [electronic resource] / $c edited by Aung Naing, Joud Hajjar.
250 $a Third edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xii, 339 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1244
505 0 $a Overview of Basic Immunology and Clinical Application -- Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: From a minor God to the Olympus -- Immunotherapy in Gastrointestinal Malignancies -- Current Landscape of Immunotherapy in Genitourinary Malignancies -- Immuno-oncology for Gynecologic Malignancies -- Immunotherapy for Neuro-Oncology -- Immunotherapy and Radiation -- CAR T-cells -- Skin Reactions to Immune Checkpoint Inhibitors -- Gastrointestinal Tract Adverse Events -- Immune-Related Adverse Events: Pneumonitis -- Hepatobiliary Adverse Events -- Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity -- Renal Toxicity -- Immune-Related Oral, Otologic and Ocular Adverse Events -- Cancer Imaging in Immunotherapy -- The Microbiome in Immuno-Oncology -- New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies.
520 $a Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
650 0 $a Immunotherapy. $3 211033
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Immunology. $3 189152
650 2 4 $a Oncology. $3 195181
700 1 $a Naing, Aung. $3 775190
700 1 $a Hajjar, Joud. $3 775191
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u https://doi.org/10.1007/978-3-030-41008-7
950 $a Biomedical and Life Sciences (Springer-11642)